T
Terrestrial
Engages in developing biomedical innovations with a focus on improving access to vaccines
About Terrestrial
Vaxess Technologies is a pioneering biotech company specializing in the development of silk-based patches for the delivery of vaccines and therapies. Operating in the healthcare and pharmaceutical markets, Vaxess aims to revolutionize the way treatments are administered by leveraging the unique properties of silk to create smart release therapies. These patches are designed to mimic infections without the associated side effects, stimulating a more powerful and durable immune response. The company serves a diverse range of clients, including healthcare providers, pharmaceutical companies, and global health organizations.
Vaxess's business model focuses on research and development, partnering with other organizations to bring innovative solutions to market. The company generates revenue through the sale of its patches and through strategic partnerships and collaborations. By offering a more efficacious flu vaccine and developing a shelf-stable, self-applied SARS-CoV-2 vaccine, Vaxess is positioned to make significant contributions to global health.
The core technology involves applying a patch to the skin, where silk tips dissolve at a precise rate, releasing the treatment at its most effective dose over time. This method eliminates the need for needles and allows for a quick, simple, and painless application process. The patches can deliver treatments over a period ranging from minutes to months, making them highly versatile and effective.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Cambridge, United States
- Employees
- 105
- Open positions
- 4
- Dealroom signal
- 94.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Vaccines, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | May 2026 | $1.4M | — | Massachusetts Life Sciences Center | ↗ |
| GRANTOther financing | Apr 2026 | $850K | — | Massachusetts eHealth Institute | ↗ |
Growth signals
Latest recorded traffic for Terrestrial is 3.2K monthly website visits, up 580.9% over the last three months. Terrestrial's team grew 87.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
MassChallenge
Bill & Melinda Gates Foundation
National Institutes of Health
US National Science Foundation
National Institute of Diabetes and Digestive and Kidney Diseases
Massachusetts eHealth Institute
Series A5 investors entered at this stage
Norwich Ventures
The Engine
RA Capital Management
Global Health Investment Corporation
Mission BioCapital
Series B and later2 investors entered at this stage
Massachusetts Life Sciences Center
Engine Ventures
Other known investors1 additional known investor
Tufts University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Terrestrial on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Terrestrial’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







